Clinical Trial Update: Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates nilotinib for prevention of paclitaxel-induced peripheral neuropathy in patients with Stage I-III breast cancer; results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 1 | Status: COMPLETED | Results posted: 2025-06-29